{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,4]],"date-time":"2026-11-04T22:31:25Z","timestamp":1793831485186,"version":"4.6.1"},"reference-count":39,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2025,10,6]],"date-time":"2025-10-06T00:00:00Z","timestamp":1759708800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2025,10,6]],"date-time":"2025-10-06T00:00:00Z","timestamp":1759708800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Diabetes Ther"],"published-print":{"date-parts":[[2025,11]]},"DOI":"10.1007\/s13300-025-01801-z","type":"journal-article","created":{"date-parts":[[2025,10,6]],"date-time":"2025-10-06T12:47:20Z","timestamp":1759754840000},"page":"2101-2109","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":14,"title":["Diabetic Platelets: Pathophysiology, Clinical Significance, and Therapeutic Perspectives"],"prefix":"10.1007","volume":"16","author":[{"given":"Neha","family":"Sharma","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Suneet Kumar","family":"Verma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sourabh","family":"Sharma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nitin","family":"Kapoor","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1308-121X","authenticated-orcid":false,"given":"Sanjay","family":"Kalra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,10,6]]},"reference":[{"issue":"3","key":"1801_CR1","doi-asserted-by":"publisher","DOI":"10.1002\/hsr2.2004","volume":"7","author":"MJ Hossain","year":"2024","unstructured":"Hossain MJ, Al-Mamun M, Islam MR. Diabetes mellitus, the fastest growing global public health concern: early detection should be focused. Health Sci Rep. 2024;7(3):e2004.","journal-title":"Health Sci Rep"},{"issue":"5","key":"1801_CR2","doi-asserted-by":"publisher","first-page":"568","DOI":"10.21037\/cdt.2018.07.01","volume":"8","author":"M Hamilos","year":"2018","unstructured":"Hamilos M, Petousis S, Parthenakis F. Interaction between platelets and endothelium: from pathophysiology to new therapeutic options. Cardiovasc Diagn Ther. 2018;8(5):568\u201380.","journal-title":"Cardiovasc Diagn Ther"},{"issue":"5","key":"1801_CR3","doi-asserted-by":"publisher","first-page":"706","DOI":"10.3390\/antiox10050706","volume":"10","author":"AR Vaidya","year":"2021","unstructured":"Vaidya AR, Wolska N, Vara D, Mailer RK, Schr\u00f6der K, Pula G. Diabetes and thrombosis: a central role for vascular oxidative stress. Antioxidants (Basel). 2021;10(5):706.","journal-title":"Antioxidants (Basel)"},{"issue":"13","key":"1801_CR4","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.900254","volume":"29","author":"J Ye","year":"2022","unstructured":"Ye J, Li L, Wang M, Ma Q, Tian Y, Zhang Q, et\u00a0al. Diabetes mellitus promotes the development of atherosclerosis: the role of NLRP3. Front Immunol. 2022;29(13):900254.","journal-title":"Front Immunol"},{"key":"1801_CR5","doi-asserted-by":"publisher","DOI":"10.1155\/2011\/742719","volume":"2011","author":"N Kakouros","year":"2011","unstructured":"Kakouros N, Rade JJ, Kourliouros A, Resar JR. Platelet function in patients with diabetes mellitus: from a theoretical to a practical perspective. Int J Endocrinol. 2011;2011:742719.","journal-title":"Int J Endocrinol"},{"issue":"1","key":"1801_CR6","doi-asserted-by":"publisher","first-page":"18","DOI":"10.3390\/biomedicines9010018","volume":"9","author":"L Toma","year":"2020","unstructured":"Toma L, Stancu CS, Sima AV. Endothelial Dysfunction in diabetes is aggravated by glycated lipoproteins; novel molecular therapies. Biomedicines. 2020;9(1):18.","journal-title":"Biomedicines"},{"issue":"2","key":"1801_CR7","doi-asserted-by":"publisher","first-page":"241","DOI":"10.2337\/diab.39.2.241","volume":"39","author":"PD Winocour","year":"1990","unstructured":"Winocour PD, Bryszewska M, Watala C, Rand ML, Epand RM, Kinlough-Rathbone RL, et\u00a0al. Reduced membrane fluidity in platelets from diabetic patients. Diabetes. 1990;39(2):241\u20134.","journal-title":"Diabetes"},{"issue":"1","key":"1801_CR8","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1038\/s41392-025-02198-8","volume":"10","author":"Y Tian","year":"2025","unstructured":"Tian Y, Zong Y, Pang Y, Zheng Z, Ma Y, Zhang C, et\u00a0al. Platelets and diseases: signal transduction and advances in targeted therapy. Signal Transduct Target Ther. 2025;10(1):159.","journal-title":"Signal Transduct Target Ther"},{"issue":"5","key":"1801_CR9","doi-asserted-by":"publisher","first-page":"332","DOI":"10.1007\/BF00405005","volume":"34","author":"H Ishii","year":"1991","unstructured":"Ishii H, Umeda F, Hashimoto T, Nawata H. Increased intracellular calcium mobilization in platelets from patients with type 2 (non-insulin-dependent) diabetes mellitus. Diabetologia. 1991;34(5):332\u20136.","journal-title":"Diabetologia"},{"issue":"6","key":"1801_CR10","doi-asserted-by":"publisher","first-page":"423","DOI":"10.4093\/dmj.2013.37.6.423","volume":"37","author":"JH Kim","year":"2013","unstructured":"Kim JH, Bae HY, Kim SY. Clinical marker of platelet hyperreactivity in diabetes mellitus. Diabetes Metab J. 2013;37(6):423\u20138.","journal-title":"Diabetes Metab J"},{"issue":"20","key":"1801_CR11","doi-asserted-by":"publisher","first-page":"15328","DOI":"10.3390\/ijms242015328","volume":"24","author":"NZ Safdar","year":"2023","unstructured":"Safdar NZ, Kietsiriroje N, Ajjan RA. The cellular and protein arms of coagulation in diabetes: established and potential targets for the reduction of thrombotic risk. Int J Mol Sci. 2023;24(20):15328.","journal-title":"Int J Mol Sci"},{"issue":"14","key":"1801_CR12","doi-asserted-by":"publisher","first-page":"4866","DOI":"10.3390\/ijms21144866","volume":"21","author":"E Masselli","year":"2020","unstructured":"Masselli E, Pozzi G, Vaccarezza M, Mirandola P, Galli D, Vitale M, et\u00a0al. ROS in platelet biology: functional aspects and methodological insights. Int J Mol Sci. 2020;21(14):4866.","journal-title":"Int J Mol Sci"},{"issue":"8","key":"1801_CR13","doi-asserted-by":"publisher","first-page":"6651","DOI":"10.3390\/cimb45080420","volume":"45","author":"A Caturano","year":"2023","unstructured":"Caturano A, D\u2019Angelo M, Mormone A, Russo V, Mollica MP, Salvatore T, et\u00a0al. Oxidative stress in type 2 diabetes: impacts from pathogenesis to lifestyle modifications. Curr Issues Mol Biol. 2023;45(8):6651\u201366.","journal-title":"Curr Issues Mol Biol"},{"issue":"11","key":"1801_CR14","doi-asserted-by":"publisher","first-page":"1483","DOI":"10.7150\/ijbs.27173","volume":"14","author":"X Huang","year":"2018","unstructured":"Huang X, Liu G, Guo J, Su Z. The PI3K\/AKT pathway in obesity and type 2 diabetes. Int J Biol Sci. 2018;14(11):1483\u201396.","journal-title":"Int J Biol Sci"},{"issue":"1","key":"1801_CR15","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/S0168-8227(00)00160-1","volume":"50","author":"AB Sobol","year":"2000","unstructured":"Sobol AB, Watala C. The role of platelets in diabetes-related vascular complications. Diabetes Res Clin Pract. 2000;50(1):1\u201316.","journal-title":"Diabetes Res Clin Pract"},{"key":"1801_CR16","doi-asserted-by":"crossref","unstructured":"Prabhu S, Sharma R, Peter K. Platelets in the pathogenesis of vascular disease and their role as a therapeutic target. In: Fitridge R, Thompson M, editors. Mechanisms of vascular disease: a reference book for vascular specialists [Internet]. Adelaide (AU): University of Adelaide Press; 2011. 11. https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK534273\/. Accessed 16 July 2025.","DOI":"10.1017\/UPO9781922064004.012"},{"key":"1801_CR17","doi-asserted-by":"publisher","DOI":"10.1155\/2012\/909154","volume":"2012","author":"K Balasubramaniam","year":"2012","unstructured":"Balasubramaniam K, Viswanathan GN, Marshall SM, Zaman AG. Increased atherothrombotic burden in patients with diabetes mellitus and acute coronary syndrome: a review of antiplatelet therapy. Cardiol Res Pract. 2012;2012:909154.","journal-title":"Cardiol Res Pract"},{"issue":"8","key":"1801_CR18","doi-asserted-by":"publisher","first-page":"1590","DOI":"10.2337\/dc08-0282","volume":"31","author":"A Undas","year":"2008","unstructured":"Undas A, Wiek I, St\u00eapien E, Zmudka K, Tracz W. Hyperglycemia is associated with enhanced thrombin formation, platelet activation, and fibrin clot resistance to lysis in patients with acute coronary syndrome. Diabetes Care. 2008;31(8):1590\u20135.","journal-title":"Diabetes Care"},{"issue":"4","key":"1801_CR19","doi-asserted-by":"publisher","first-page":"531","DOI":"10.2337\/dc08-2064","volume":"32","author":"DJ Angiolillo","year":"2009","unstructured":"Angiolillo DJ. Antiplatelet therapy in diabetes: efficacy and limitations of current treatment strategies and future directions. Diabetes Care. 2009;32(4):531\u201340.","journal-title":"Diabetes Care"},{"key":"1801_CR20","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1007\/s12170-014-0430-5","volume":"9","author":"DJ Kumbhani","year":"2015","unstructured":"Kumbhani DJ, Marso SP, Alvarez CA, McGuire DK. State-of-the-Art: Hypo-responsiveness to oral antiplatelet therapy in patients with type 2 diabetes mellitus. Curr Cardiovasc Risk Rep. 2015;9:4.","journal-title":"Curr Cardiovasc Risk Rep"},{"issue":"1","key":"1801_CR21","doi-asserted-by":"publisher","first-page":"52","DOI":"10.2337\/dci23-0078","volume":"47","author":"D Aguilar","year":"2024","unstructured":"Aguilar D, Davis BR. Aspirin dosing in cardiovascular disease and diabetes: insights from ADAPTABLE. Diabetes Care. 2024;47(1):52\u20133.","journal-title":"Diabetes Care"},{"issue":"1","key":"1801_CR22","doi-asserted-by":"publisher","first-page":"8","DOI":"10.3390\/jpm8010008","volume":"8","author":"SA Brown","year":"2018","unstructured":"Brown SA, Pereira N. Pharmacogenomic impact of CYP2C19 variation on clopidogrel therapy in precision cardiovascular medicine. J Pers Med. 2018;8(1):8.","journal-title":"J Pers Med"},{"issue":"4","key":"1801_CR23","doi-asserted-by":"publisher","first-page":"697","DOI":"10.1111\/j.1365-2125.2011.03949.x","volume":"72","author":"TK Ma","year":"2011","unstructured":"Ma TK, Lam YY, Tan VP, Yan BP. Variability in response to clopidogrel: how important are pharmacogenetics and drug interactions? Br J Clin Pharmacol. 2011;72(4):697\u2013706.","journal-title":"Br J Clin Pharmacol"},{"issue":"5\u20136","key":"1801_CR24","doi-asserted-by":"publisher","first-page":"152","DOI":"10.1016\/j.vph.2013.10.002","volume":"59","author":"NL Hurst","year":"2013","unstructured":"Hurst NL, Nooney VB, Raman B, Chirkov YY, De Caterina R, Horowitz JD. Clopidogrel \u201cresistance\u201d: pre- vs post-receptor determinants. Vascul Pharmacol. 2013;59(5\u20136):152\u201361.","journal-title":"Vascul Pharmacol."},{"issue":"6","key":"1801_CR25","doi-asserted-by":"publisher","first-page":"708","DOI":"10.1161\/CIRCULATIONAHA.106.667741","volume":"115","author":"DJ Angiolillo","year":"2007","unstructured":"Angiolillo DJ, Shoemaker SB, Desai B, Yuan H, Charlton RK, Bernardo E, et\u00a0al. Randomized comparison of a high clopidogrel maintenance dose in patients with diabetes mellitus and coronary artery disease: results of the Optimizing Antiplatelet Therapy in Diabetes Mellitus (OPTIMUS) study. Circulation. 2007;115(6):708\u201316.","journal-title":"Circulation"},{"issue":"7","key":"1801_CR26","doi-asserted-by":"publisher","first-page":"1987","DOI":"10.3390\/molecules26071987","volume":"26","author":"MA Akkaif","year":"2021","unstructured":"Akkaif MA, Daud NAA, Sha\u2019aban A, Ng ML, Abdul Kader MAS, Noor DAM, et\u00a0al. The role of genetic polymorphism and other factors on clopidogrel resistance (CR) in an Asian population with coronary heart disease (CHD). Molecules. 2021;26(7):1987.","journal-title":"Molecules"},{"issue":"9","key":"1801_CR27","doi-asserted-by":"publisher","DOI":"10.3389\/fcvm.2022.805525","volume":"28","author":"G Jourdi","year":"2022","unstructured":"Jourdi G, Godier A, Lordkipanidz\u00e9 M, Marquis-Gravel G, Gaussem P. Antiplatelet therapy for atherothrombotic disease in 2022-from population to patient-centered approaches. Front Cardiovasc Med. 2022;28(9):805525.","journal-title":"Front Cardiovasc Med"},{"issue":"3","key":"1801_CR28","doi-asserted-by":"publisher","first-page":"342","DOI":"10.1111\/jcpt.12651","volume":"43","author":"LL Shang","year":"2018","unstructured":"Shang LL, Guo DD, Zhao HY, Quan AJ, Cao PG. Comparison of pharmacodynamic effects of ticagrelor vs prasugrel in type 2 diabetes mellitus patients with coronary heart disease. J Clin Pharm Ther. 2018;43(3):342\u20137.","journal-title":"J Clin Pharm Ther"},{"issue":"4","key":"1801_CR29","doi-asserted-by":"publisher","first-page":"647","DOI":"10.1111\/j.1365-2125.2011.03999.x","volume":"72","author":"YD Wijeyeratne","year":"2011","unstructured":"Wijeyeratne YD, Heptinstall S. Anti-platelet therapy: ADP receptor antagonists. Br J Clin Pharmacol. 2011;72(4):647\u201357.","journal-title":"Br J Clin Pharmacol"},{"issue":"12","key":"1801_CR30","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2021.670155","volume":"12","author":"A Nusca","year":"2021","unstructured":"Nusca A, Tuccinardi D, Pieralice S, Giannone S, Carpenito M, Monte L, et\u00a0al. Platelet effects of anti-diabetic therapies: new perspectives in the management of patients with diabetes and cardiovascular disease. Front Pharmacol. 2021;12(12):670155.","journal-title":"Front Pharmacol"},{"issue":"8","key":"1801_CR31","doi-asserted-by":"publisher","first-page":"1609","DOI":"10.3390\/antiox12081609","volume":"12","author":"C Barale","year":"2023","unstructured":"Barale C, Melchionda E, Tempesta G, Morotti A, Russo I. Impact of physical exercise on platelets: focus on its effects in metabolic chronic diseases. Antioxidants (Basel). 2023;12(8):1609.","journal-title":"Antioxidants (Basel)"},{"issue":"5","key":"1801_CR32","doi-asserted-by":"publisher","first-page":"633","DOI":"10.1080\/09537104.2019.1668549","volume":"31","author":"TA Blair","year":"2020","unstructured":"Blair TA, Frelinger AL 3rd. Platelet surface marker analysis by mass cytometry. Platelets. 2020;31(5):633\u201340.","journal-title":"Platelets"},{"issue":"1","key":"1801_CR33","doi-asserted-by":"publisher","DOI":"10.1080\/09537104.2024.2427745","volume":"35","author":"A St\u00e9panian","year":"2024","unstructured":"St\u00e9panian A, Fischer F, Flaujac C, Eschw\u00e8ge V, Delassasseigne C, Leflem L, et\u00a0al. Light transmission aggregometry for platelet function testing: position paper on current recommendations and French proposals for accreditation. Platelets. 2024;35(1):2427745.","journal-title":"Platelets"},{"issue":"Feb 18","key":"1801_CR34","doi-asserted-by":"publisher","first-page":"133","DOI":"10.2147\/VHRM.S44469","volume":"11","author":"R Paniccia","year":"2015","unstructured":"Paniccia R, Priora R, Liotta AA, Abbate R. Platelet function tests: a comparative review. Vasc Health Risk Manag. 2015;11(Feb 18):133\u201348.","journal-title":"Vasc Health Risk Manag"},{"issue":"1","key":"1801_CR35","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1046\/j.1365-2141.1998.00656.x","volume":"101","author":"MD Carcao","year":"1998","unstructured":"Carcao MD, Blanchette VS, Dean JA, He L, Kern MA, Stain AM, et\u00a0al. The platelet function analyzer (PFA-100): a novel in-vitro system for evaluation of primary haemostasis in children. Br J Haematol. 1998;101(1):70\u20133.","journal-title":"Br J Haematol"},{"issue":"15","key":"1801_CR36","doi-asserted-by":"publisher","first-page":"1423428","DOI":"10.3389\/fmicb.2024.1423428","volume":"22","author":"YH Luo","year":"2024","unstructured":"Luo YH, Wang DW, Yao J, Hu Y, Zhao L, Wen JX, et\u00a0al. Integrated metabolomics and transcriptomics analysis reveals the mechanism of Tangbi capsule for diabetic lower extremities arterial disease. Front Microbiol. 2024;22(15):1423428.","journal-title":"Front Microbiol"},{"issue":"9","key":"1801_CR37","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2022.911861","volume":"1","author":"X Dai","year":"2022","unstructured":"Dai X, Shen L. Advances and trends in omics technology development. Front Med (Lausanne). 2022;1(9):911861.","journal-title":"Front Med (Lausanne)"},{"issue":"1","key":"1801_CR38","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1038\/s41392-023-01399-3","volume":"8","author":"S Qiu","year":"2023","unstructured":"Qiu S, Cai Y, Yao H, Lin C, Xie Y, Tang S, et\u00a0al. Small molecule metabolites: discovery of biomarkers and therapeutic targets. Signal Transduct Target Ther. 2023;8(1):132.","journal-title":"Signal Transduct Target Ther"},{"issue":"9","key":"1801_CR39","doi-asserted-by":"publisher","first-page":"4973","DOI":"10.3390\/ijms23094973","volume":"23","author":"RC Sagar","year":"2022","unstructured":"Sagar RC, Ajjan RA, Naseem KM. Non-traditional pathways for platelet pathophysiology in diabetes: implications for future therapeutic targets. Int J Mol Sci. 2022;23(9):4973.","journal-title":"Int J Mol Sci"}],"container-title":["Diabetes Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13300-025-01801-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s13300-025-01801-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13300-025-01801-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T22:10:04Z","timestamp":1761948604000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s13300-025-01801-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,6]]},"references-count":39,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2025,11]]}},"alternative-id":["1801"],"URL":"https:\/\/doi.org\/10.1007\/s13300-025-01801-z","relation":{},"ISSN":["1869-6953","1869-6961"],"issn-type":[{"value":"1869-6953","type":"print"},{"value":"1869-6961","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10,6]]},"assertion":[{"value":"12 August 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 September 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 October 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors, Neha Sharma, Suneet Kumar Verma, Sourabh Sharma, Nitin Kapoor and Sanjay Kalra, have nothing to disclose. Sanjay Kalra is an Editorial Board member of Diabetes Therapy. Sanjay Kalra was not involved in the selection of peer reviewers for the manuscript nor any of the subsequent editorial decisions.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"This article is based on previously conducted studies and does not contain any new studies with human participants or animals performed by any of the authors.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics Approval"}}]}}